DUBLIN--(BUSINESS WIRE)--The "North America Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Analysis (2018-2024)" report has been added to ResearchAndMarkets.com's offering.
The factors driving the market include rapid rise in geriatric population, who are more prone to ophthalmology diseases such as glaucoma and cataract. The novel paradigm of glaucoma therapy by using MIGS devices will aspire to a much reduced dependence on topical medication. In addition, increasing preference of surgeons for MIGS is adding boost to the market growth.
On the basis of Surgery, the market is segmented into Glaucoma in Conjunction with Cataract and Stand Alone Glaucoma. Target is categorized into Trabecular Meshwork, Suprachoroidal Space and Other Targets. On the basis of Product, the market is segmented into MIGS Stents, MIGS Shunts and Other Products. The End Users covered under the report are Eye Hospitals, Ophthalmology Clinics and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Key Topics Covered
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. North America Minimally Invasive Glaucoma Surgery (MIGS) Devices Market by Surgery
Chapter 4. North America Minimally Invasive Glaucoma Surgery (MIGS) Devices Market by Target
Chapter 5. North America Minimally Invasive Glaucoma Surgery (MIGS) Devices Market by Product
Chapter 6. North America Minimally Invasive Glaucoma Surgery (MIGS) Devices Market by End User
Chapter 7. North America Minimally Invasive Glaucoma Surgery (MIGS) Devices Market by Country
Chapter 8. Company Profiles
- Ellex Medical Lasers Ltd.
- Allergan PLC
- Santen Pharmaceutical Co. Ltd.
- Glaukos Corporation
- Alcon Inc. (Novartis)
- Lumenis
- Ivantis, Inc.
- iSTAR Medical
- InnFocus Inc.
- SOLX, Inc.
For more information about this report visit https://www.researchandmarkets.com/research/rk784z/minimally?w=4
